Free Trial Information
BioCentury | Mar 4, 2021
Deals

How Pandion’s triple-digit premium ranks among recent biotech takeouts: Data Byte

The takeout of Pandion Therapeutics Inc. (NASDAQ:PAND) by Merck & Co. Inc. (NYSE:MRK) last week came at a per-share price more than double the immunology company’s all-time intraday high and a 134% premium over its...
Read More
BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

The COVID-19 pandemic didn’t stand in the way of new drug approvals by FDA in 2020, but few new modalities crossed the finish line despite the clinical development fervor around platform technologies and...
Read More
BioCentury | Dec 31, 2020
Distillery Therapeutics

SIRT5 overexpression could rescue mitochondrial disease induced by SUCLA2 mutations

...2020doi:10.1038/s41467-020-19743-4CONTACT: Philipp Gut, Gladstone Institutes and University of California, San Francisco, Calif.; Nestlé Institute of Health Sciences, Lausanne, Switzerlandemail: philipp.gut@rd.nestle.comCONTACT: Birgit...
Read More
BioCentury | Oct 6, 2020
Management Tracks

BioMarin, Sanofi tap new execs for early R&D positions

...Sanofi promotes Nestle to head of research, CSO; Eggan joins BioMarin By Paul Bonanos, Associate Editor...
...Corp., each of which has programs to treat amyotrophic lateral sclerosis.Sanofi (Euronext:SAN; NASDAQ:SNY) promoted Frank Nestle...
...global head of immunology and CSO for North America. The company is combining both of Nestle’s...
Read More
BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...21FLT3 (CD135) - FMS-like tyrosine kinase 3 BC Staff NIH 89bio Takeda Nestle S.A. AIMM...
Read More
BioCentury | Aug 31, 2020
Deals

Takeout premium shows Nestlé’s faith in Aimmune peanut product, despite launch slowed by COVID

...– Immunoglobulin E Paul Bonanos Palforzia, peanut allergen powder (AR101, arc001, peanut allergy oral immunotherapy (oit)) Nestle Health Science Nestle S.A. Aimmune...
Read More
BioCentury | Aug 11, 2020
Product Development

Phase II learnings set up microbiome play Seres for Phase III success

Seres parlayed lessons learned from the failed Phase II trial of SER-109 to treat recurrent C. difficile infection into a Phase III win through improved patient selection and higher dosing. Seres Therapeutics Inc. (NASDAQ:MCRB) added...
Read More
BioCentury | Jul 25, 2020
Translation in Brief

New class of cytosine base editors; plus new U.K. vaccine manufacturing facilities, scalable surrogate assay for COVID-19; combating antibiotic resistance and

New base editors widen template-free editing options A Massachusetts General Hospital team co-led by Beam Therapeutics Inc. (NASDAQ:BEAM) co-founder Keith Joung, and a Chinese Academy of Sciences team have separately developed a new class of...
Read More
BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

Chi-Med raises $100M private placement Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) raised $100 million Thursday in a private placement to General Atlantic through the sale of 4 million ADSs at $25. The price matches its...
Read More
BioCentury | Apr 17, 2020
Product Development

Seeking safe microbiome therapies amid COVID-19 crisis

...bacterial spore therapy SER-109 is in Phase III testing for recurrent CDI and co-developed with Nestle S.A....
Read More
Items per page:
1 - 10 of 198
BioCentury | Mar 4, 2021
Deals

How Pandion’s triple-digit premium ranks among recent biotech takeouts: Data Byte

The takeout of Pandion Therapeutics Inc. (NASDAQ:PAND) by Merck & Co. Inc. (NYSE:MRK) last week came at a per-share price more than double the immunology company’s all-time intraday high and a 134% premium over its...
Read More
BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

The COVID-19 pandemic didn’t stand in the way of new drug approvals by FDA in 2020, but few new modalities crossed the finish line despite the clinical development fervor around platform technologies and...
Read More
BioCentury | Dec 31, 2020
Distillery Therapeutics

SIRT5 overexpression could rescue mitochondrial disease induced by SUCLA2 mutations

...2020doi:10.1038/s41467-020-19743-4CONTACT: Philipp Gut, Gladstone Institutes and University of California, San Francisco, Calif.; Nestlé Institute of Health Sciences, Lausanne, Switzerlandemail: philipp.gut@rd.nestle.comCONTACT: Birgit...
Read More
BioCentury | Oct 6, 2020
Management Tracks

BioMarin, Sanofi tap new execs for early R&D positions

...Sanofi promotes Nestle to head of research, CSO; Eggan joins BioMarin By Paul Bonanos, Associate Editor...
...Corp., each of which has programs to treat amyotrophic lateral sclerosis.Sanofi (Euronext:SAN; NASDAQ:SNY) promoted Frank Nestle...
...global head of immunology and CSO for North America. The company is combining both of Nestle’s...
Read More
BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...21FLT3 (CD135) - FMS-like tyrosine kinase 3 BC Staff NIH 89bio Takeda Nestle S.A. AIMM...
Read More
BioCentury | Aug 31, 2020
Deals

Takeout premium shows Nestlé’s faith in Aimmune peanut product, despite launch slowed by COVID

...– Immunoglobulin E Paul Bonanos Palforzia, peanut allergen powder (AR101, arc001, peanut allergy oral immunotherapy (oit)) Nestle Health Science Nestle S.A. Aimmune...
Read More
BioCentury | Aug 11, 2020
Product Development

Phase II learnings set up microbiome play Seres for Phase III success

Seres parlayed lessons learned from the failed Phase II trial of SER-109 to treat recurrent C. difficile infection into a Phase III win through improved patient selection and higher dosing. Seres Therapeutics Inc. (NASDAQ:MCRB) added...
Read More
BioCentury | Jul 25, 2020
Translation in Brief

New class of cytosine base editors; plus new U.K. vaccine manufacturing facilities, scalable surrogate assay for COVID-19; combating antibiotic resistance and

New base editors widen template-free editing options A Massachusetts General Hospital team co-led by Beam Therapeutics Inc. (NASDAQ:BEAM) co-founder Keith Joung, and a Chinese Academy of Sciences team have separately developed a new class of...
Read More
BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

Chi-Med raises $100M private placement Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) raised $100 million Thursday in a private placement to General Atlantic through the sale of 4 million ADSs at $25. The price matches its...
Read More
BioCentury | Apr 17, 2020
Product Development

Seeking safe microbiome therapies amid COVID-19 crisis

...bacterial spore therapy SER-109 is in Phase III testing for recurrent CDI and co-developed with Nestle S.A....
Read More
Items per page:
1 - 10 of 198